Breast cancer as an acquired thrombophilic state

Journal of Breast Cancer

Volumn 15, Issue 2, 2012, Pages 148-156

  Kyriazi, Vasiliki ^a  

^a Central Polyclinic   (Greece)

Author keywords

Blood coagulation; Breast neoplasms; Hemostasis; Thrombosis

Indexed keywords

ANASTROZOLE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; APIXABAN; CANCER PROCOAGULANT; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; D DIMER; DABIGATRAN; DALTEPARIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FLUOROURACIL; FONDAPARINUX; HEPARIN; INTERLEUKIN 1BETA; LOW MOLECULAR WEIGHT HEPARIN; MEDROXYPROGESTERONE; METHOTREXATE; PREDNISOLONE; PROTEIN C; PROTEIN S; RIVAROXABAN; SEMULOPARIN; TAMOXIFEN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; WARFARIN;

ARTERY THROMBOSIS; BLOOD CLOTTING TEST; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR EQUIPMENT; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; COMPRESSION GARMENT; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOGEN BLOOD LEVEL; HUMAN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MACROPHAGE; MASTECTOMY; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PATHOPHYSIOLOGY; PROTHROMBIN TIME; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; THROMBOCYTOSIS; THROMBOPHILIA; THROMBOSIS PREVENTION; VENOUS FOOT PUMP DEVICE; VENOUS THROMBOEMBOLISM;

EID: 84865111170     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.2.148     Document Type: Review

References (45)

1. Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009;29:316-20.
2. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-6.
3. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Doubleblind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9.
4. Polite BN, Lamont EB. Are venous thromboembolic events associated with subsequent breast and colorectal carcinoma diagnoses in the elderly? A case-control study of Medicare beneficiaries. Cancer 2006;106: 923-30.
5. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-64.
6. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
7. Fanale MA, Zeldenrust SR, Moynihan TJ. Some unusual complications of malignancies: case 2. Marantic endocarditis in advanced cancer. J Clin Oncol 2002;20:4111-4.
8. Prandoni P, Lensing AW, Büller HR, Cogo A, Prins MH, Cattelan AM, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-33.
9. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005;31: 104-10.
10. Boccaccio C, Comoglio PM. Oncogenes, cancer, and hemostasis. In: Khorana AA, Francis CW, editors. Cancer-associated Thrombosis New Findings in Translational Science, Prevention, and Treatment. London: Informa Healthcare; 2007. p.10-23.
11. Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract 2011;2011:394740.
12. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
13. Fernadez PM, Patierno SR, Rickles FR. Tumor angiogenesis and blood coagulation. In: Lugassy G, Falanga A, Kakkar AK, Rickles FR, editors. Thrombosis and Cancer. London: Martin Dunitz; 2004.
14. Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009;7:1421-3.
15. Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R, Zembala M, Barbasz J, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother 2010;59:841-50.
16. Andtbacka RH, Babiera G, Singletary SE, Hunt KK, Meric-Bernstam F, Feig BW, et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 2006;243:96-101.
17. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994;12:1266-71.
18. Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer 2003;98:1578-86.
19. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984;54:1264-8.
20. Wall JG, Weiss RB, Norton L, Perloff M, Rice MA, Korzun AH, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B study. Am J Med 1989;87: 501-4.
21. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94.
22. Rogers JS 2nd, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988;6:276-81.
23. Lee JJ, Yu JY, Lee JH, Zhang WY, Kim TJ, Myung CS, et al. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase. Arch Pharm Res 2010;33:387-94.
24. Napoleone E, Zurlo F, Latella MC, Amore C, Di Santo A, Iacoviello L, et al. Paclitaxel downregulates tissue factor in cancer and host tumourassociated cells. Eur J Cancer 2009;45:470-7.
25. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 1995;311:977-80.
26. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997;79:2024-7.
27. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, et al. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 2004;15:1622-6.
28. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-9.
29. Acedo Sánchez JD, Batlle JF, Feijoo JB. Catheter-related thrombosis: a critical review. Support Cancer Ther 2007;4:145-51.
30. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004;9:207-16.
31. Schwarz RE, Coit DG, Groeger JS. Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection. Ann Surg Oncol 2000;7: 441-9.
32. Mandalà M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004;15:590-3.
33. Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006;24:1112-8.
34. Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I, et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost 2008;100:663-9.
35. Caine GJ, Stonelake PS, Lip GY, Blann AD. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer. Cancer Lett 2007;248:131-6.
36. Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer 2008;99:1000-6.
37. Lee AY. Diagnosis and treatment of cancer-related thrombosis. Hematol Educ 2010;4:306-10.
38. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-9.
39. Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009;27:4919-26.
40. Levine MN, Deitchman D, Julian J, Liebman H, Escalante C, O'Brien MC, et al. A randomized phase II trial of a new anticoagulant apixaban, in metastatic cancer. 2009 ASCO Annual Meeting 2009;27. Abstract #20514.
41. Hoppensteadt D, Jeske W, Walenga JM, Fareed J. AVE5026: A new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antothrombotic activity for management of cancer associated thrombosis. 2008 ASCO Annual Meeting 2008;26. Abstract #14653.
42. Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol 2010;3:3.
43. Kirwan CC, McDowell G, McCollum CN, Byrne GJ. Incidence of venous thromboembolism during chemotherapy for breast cancer: impact on cancer outcome. Anticancer Res 2011;31:2383-8.
44. Prestidge T, Lee S, Harper P, Young L, Ockelford P. Survival in patients with malignancy and venous thromboembolism by tumour subtype and thrombus location. Intern Med J 2012;42:71-4.
45. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-5.